Life Sciences Blog

AstraZeneca partners with Isis Pharmaceuticals

Posted on December 11th, by Michael Shapiro-Barr

AstraZeneca and Isis Pharmaceuticals Inc. have formed a partnership to develop cancer therapies.  AstraZeneca will co-develop four oncology research programs, gaining rights to develop and commercialize a drug in early trials for patients with advanced lymphomas.  The deal includes $31 million in upfront and near-term payments to Isis.

Read More



Comments are closed.

Recent Posts

Enter your email address to subscribe to this blog and receive notifications of new posts by email.


From the Blog

Where to Spend Your Healthcare Investment Dollars

In a blog entry written over the summer, I expressed the view that the next 5-10 years will present tremendous transactional opportunities in the life...

Second Circuit Rejects Government’s Off-Label Enforcement Approach

Last week’s decision in the off-label promotion case, United States v. Caronia, No. 09-5006-cr (2d Cir. Dec. 3, 2012), is an important blow to...

Massachusetts Refines Its Sunshine Law; Final Federal Sunshine Regulations Moving Ahead

The relationship between health care providers and drug and device manufacturers has been a focus of lawmakers at both the federal and state level. ...

Subscribe by Email for New Blog Posts